Cytopia Vows Fight To Keep Avexa From Progen In All-Australia Battle
This article was originally published in PharmAsia News
Executive SummaryAustralia's Cytopia is urging shareholders of Avexa to vote for its firm to merge with the biotech in late March to stave off any new hostile takeovers. Cytopia CEO Andrew Macdonald said he is not through yet in his battle to keep Progen Pharmaceuticals from trying to obtain control of Avexa, and urged shareholders to ignore Progen's promise it is ready to begin commercializing Avexa's PI-88 drug and already is in talks with Taiwain regulators. Cytopia said in an interview the Progen assertion was just a smokescreen. (Click here for more
You may also be interested in...
Crude heparin supplier Yibin Lihao headlines list of facilities in 12 countries added to the US FDA’s drug GMP import alert.
Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.
Agency hasn't named the celebrity that will participate in the study on the impact that celebrity and non-celebrity endorsements have on consumer perceptions about Rx drugs.